Cargando…

Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma

SIMPLE SUMMARY: Mucinous ovarian carcinoma (MOC) is a unique type of ovarian cancer. While many MOC patients have excellent survival, patients who experience recurrence have extremely poor prognosis. Identifying patients at the highest risk of recurrence is important for identifying which patients n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hollis, Robert L., Stillie, Lorna J., Hopkins, Samantha, Bartos, Clare, Churchman, Michael, Rye, Tzyvia, Nussey, Fiona, Fegan, Scott, Nirsimloo, Rachel, Inman, Gareth J., Herrington, C. Simon, Gourley, Charlie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616033/ https://www.ncbi.nlm.nih.gov/pubmed/34830992 http://dx.doi.org/10.3390/cancers13225839

Ejemplares similares

Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
por: Hollis, Robert L., et al.
Publicado: (2022)

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma
por: Hollis, Robert L., et al.
Publicado: (2019)

Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification
por: Hollis, Robert L., et al.
Publicado: (2021)

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
por: Hollis, Robert L., et al.
Publicado: (2020)

Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse
por: Hollis, Robert L., et al.
Publicado: (2019)

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
por: Hollis, Robert L., et al.
Publicado: (2018)

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma
por: Hollis, Robert L., et al.
Publicado: (2023)

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum
por: Hollis, Robert L., et al.
Publicado: (2019)

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
por: Hollis, Robert L., et al.
Publicado: (2022)

Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer
por: Langdon, Simon P., et al.
Publicado: (2020)

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
por: Xintaropoulou, Chrysi, et al.
Publicado: (2018)

Genetic and molecular changes in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2016)

Erratum to Genetic and molecular changes in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

Therapeutic options for mucinous ovarian carcinoma☆
por: Gorringe, Kylie L., et al.
Publicado: (2020)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

The molecular origin and taxonomy of mucinous ovarian carcinoma
por: Cheasley, Dane, et al.
Publicado: (2019)

Clinicopathological Characteristics and Prognostic Prediction in Pseudomyxoma Peritonei Originating From Mucinous Ovarian Cancer
por: Fu, Fengxian, et al.
Publicado: (2021)

Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive
por: Gourley, Charlie
Publicado: (2019)

Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge
por: Symeonides, Stefan, et al.
Publicado: (2015)

Clinicopathological and Molecular Features of Colorectal Cancer Patients With Mucinous and Non-Mucinous Adenocarcinoma
por: Lan, Yuan-Tzu, et al.
Publicado: (2021)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

Clinicopathological and genomic features of breast mucinous carcinoma
por: Lu, Kebin, et al.
Publicado: (2020)

HER2 Amplification and Clinicopathological Characteristics in a Large Asian Cohort of Rare Mucinous Ovarian Cancer
por: Chay, Wen-Yee, et al.
Publicado: (2013)

Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma
por: Tian, Qifang, et al.
Publicado: (2016)

Analysis of Clinicopathological Features of Cervical Mucinous Adenocarcinoma with a Solitary Ovarian Metastatic Mass as the First Manifestation
por: Liu, Shuanghuan, et al.
Publicado: (2020)

Mucinous cholangiocarcinoma: Clinicopathological features of the rarest type of cholangiocarcinoma
por: Sumiyoshi, Tatsuaki, et al.
Publicado: (2017)

Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma
por: Sun, Fei, et al.
Publicado: (2018)

Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment
por: Wang, Yicong, et al.
Publicado: (2023)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

Mucinous adenocarcinoma and non-mucinous adenocarcinoma: differing clinicopathological characteristics and computed tomography features in gastric cancer
por: Zhao, Jianxi, et al.
Publicado: (2017)

Gastric Mucinous Cancer Histology: Clinicopathological Characteristics and Prognostic Value
por: Jian-Hui, Chen, et al.
Publicado: (2016)

Mucinous Breast Carcinoma: Clinicopathological Comparison With Invasive Ductal Carcinoma
por: Hashmi, Atif A, et al.
Publicado: (2021)

Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer
por: Huang, An, et al.
Publicado: (2021)

Role of magnetic resonance imaging in the differentiation of mucinous ovarian carcinoma and mucinous borderline ovarian tumors
por: Hasbay, Ebru, et al.
Publicado: (2023)

Mucin-hypersecreting bile duct neoplasm characterized by clinicopathological resemblance to intraductal papillary mucinous neoplasm (IPMN) of the pancreas
por: Yamashita, Yo-ichi, et al.
Publicado: (2007)

Retrospective study of characteristics and hyperthermia intraperitoneal perfusion in mucinous borderline ovarian tumor and mucinous ovarian carcinoma
por: He, Xiaoli, et al.
Publicado: (2023)

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
por: Gershenson, David M, et al.
Publicado: (2022)

The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease
por: Numata, Masakatsu, et al.
Publicado: (2012)

Mucinous neoplasms of the appendix: a current comprehensive clinicopathologic and imaging review
por: Tirumani, Sree Harsha, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7p4rbemthdshnto637tj1objfb